ACC-001
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
OBJECTIVES
Long-term safety and tolerability of ACC-001 (vanutide cridificar), an antiamyloid- beta therapeutic vaccine, was…
Vanutide cridificar (ACC-001), an immunotherapeutic vaccine, is a potentially disease-modifying therapy that aims to reduce brain…
BACKGROUND
ACC-001 is an investigational therapeutic vaccine designed to elicit antibodies against the N-terminal peptide 1-7 of…
BACKGROUND
Vanutide Cridificar (ACC-001), a novel investigational immunotherapeutic vaccine designed to elicit antibodies against…
OBJECTIVE
Multiple lines of evidence indicate that pathological accumulation of amyloid beta (Aβ) peptide in the brain is linked…
Active or passive immunotherapy is expected to slow or stop the pathological process of Alzheimer's disease (AD). Immunotherapy…
Purpose of review We reviewed clinical trials on active and passive anti-&bgr;-amyloid (A&bgr;) immunotherapy for the treatment…
Both active and passive anti-β-amyloid (Aβ) immunotherapies for the treatment of Alzheimer's disease (AD) have demonstrated…
We would like to clarify and update information in the review article by Wilcock and Colton recently published in JAD [1]. In…
Background: In a phase 2a clinical trial of AN1792 (Study 201), a potential immunotherapeutic agent for use in Alzheimer’s…